2020 ASHP治疗立场声明:抗精神病药物在治疗成年精神分裂症和分裂情感性障碍中的应用

2020-09-01 美国卫生系统药师协会 Am J Health Syst Pharm . 2020 Sep 1;

美国卫生系统药师协会(ASHP)认为精神分裂症和分裂情感性障碍是严重的精神疾病,可显著影响个人的知觉、行为、情感和认知功能。本文的主要目的是总结一代抗精神病药物和二代抗精神病药物,并针对这些药物的临床

中文标题:

2020 ASHP治疗立场声明:抗精神病药物在治疗成年精神分裂症和分裂情感性障碍中的应用

英文标题:

ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder

发布日期:

2020-09-01

简要介绍:

美国卫生系统药师协会(ASHP)认为精神分裂症和分裂情感性障碍是严重的精神疾病,可显著影响个人的知觉、行为、情感和认知功能。本文的主要目的是总结一代抗精神病药物和二代抗精神病药物,并针对这些药物的临床应用提供指导建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 ASHP治疗立场声明:抗精神病药物在治疗成年精神分裂症和分裂情感性障碍中的应用.pdf)] GetToolGuiderByIdResponse(projectId=1, id=04e171c0019e558f, title=2020 ASHP治疗立场声明:抗精神病药物在治疗成年精神分裂症和分裂情感性障碍中的应用, enTitle=ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder, guiderFrom=Am J Health Syst Pharm . 2020 Sep 1;, authorId=0, author=, summary=美国卫生系统药师协会(ASHP)认为精神分裂症和分裂情感性障碍是严重的精神疾病,可显著影响个人的知觉、行为、情感和认知功能。本文的主要目的是总结一代抗精神病药物和二代抗精神病药物,并针对这些药物的临床, cover=https://img.medsci.cn/2020923/1600872379855_2020535.jpg, journalId=0, articlesId=null, associationId=761, associationName=美国卫生系统药师协会, associationIntro=美国卫生系统药师协会(American Society of Health-System Pharmacists)成立于1942年,是国家级的专业协会,在全世界拥有30,000多位成员,代表在医院、卫生保健组织、长期监护部门、家庭保健及其他卫生系统工作的药剂师。ASHP协会宗旨是:药师的使命是提供药学保健,是提供直接的、负责的、与药物有关的医疗,目的是改善病人的生活质量。其期刊被国际著名检索工具书和数据库收录、索引。, copyright=0, guiderPublishedTime=Tue Sep 01 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>美国卫生系统药师协会(ASHP)认为精神分裂症和分裂情感性障碍是严重的精神疾病,可显著影响个人的知觉、行为、情感和认知功能。本文的主要目的是总结一代抗精神病药物和二代抗精神病药物,并针对这些药物的临床应用提供指导建议。</p> </div> </div> </div>, tagList=[TagDto(tagId=3665, tagName=抗精神病药物)], categoryList=[CategoryDto(categoryId=13, categoryName=精神心理科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=3665, guiderKeyword=抗精神病药物, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3926, appHits=126, showAppHits=0, pcHits=667, showPcHits=3800, likes=0, shares=7, comments=15, approvalStatus=1, publishedTime=Wed Sep 23 23:08:53 CST 2020, publishedTimeString=2020-09-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Sep 23 22:46:36 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:01:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 ASHP治疗立场声明:抗精神病药物在治疗成年精神分裂症和分裂情感性障碍中的应用.pdf)])
2020 ASHP治疗立场声明:抗精神病药物在治疗成年精神分裂症和分裂情感性障碍中的应用.pdf
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1186862, encodeId=81be1186862e2, content=好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939f6397479, createdName=ms6000001232615212, createdTime=Fri Jan 21 16:10:50 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064870, encodeId=84ba10648e002, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8645455729, createdName=ms6000001527744320, createdTime=Fri Oct 29 01:30:07 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059084, encodeId=0b491059084f4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059083, encodeId=6955105908372, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:23 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059082, encodeId=dec5105908230, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:20 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2022-01-21 ms6000001232615212

    好好学习天天向上

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1186862, encodeId=81be1186862e2, content=好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939f6397479, createdName=ms6000001232615212, createdTime=Fri Jan 21 16:10:50 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064870, encodeId=84ba10648e002, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8645455729, createdName=ms6000001527744320, createdTime=Fri Oct 29 01:30:07 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059084, encodeId=0b491059084f4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059083, encodeId=6955105908372, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:23 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059082, encodeId=dec5105908230, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:20 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-10-29 ms6000001527744320

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1186862, encodeId=81be1186862e2, content=好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939f6397479, createdName=ms6000001232615212, createdTime=Fri Jan 21 16:10:50 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064870, encodeId=84ba10648e002, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8645455729, createdName=ms6000001527744320, createdTime=Fri Oct 29 01:30:07 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059084, encodeId=0b491059084f4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059083, encodeId=6955105908372, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:23 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059082, encodeId=dec5105908230, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:20 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-10-10 ms4000000833791793

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1186862, encodeId=81be1186862e2, content=好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939f6397479, createdName=ms6000001232615212, createdTime=Fri Jan 21 16:10:50 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064870, encodeId=84ba10648e002, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8645455729, createdName=ms6000001527744320, createdTime=Fri Oct 29 01:30:07 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059084, encodeId=0b491059084f4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059083, encodeId=6955105908372, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:23 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059082, encodeId=dec5105908230, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:20 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-10-10 ms4000000833791793

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1186862, encodeId=81be1186862e2, content=好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939f6397479, createdName=ms6000001232615212, createdTime=Fri Jan 21 16:10:50 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064870, encodeId=84ba10648e002, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8645455729, createdName=ms6000001527744320, createdTime=Fri Oct 29 01:30:07 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059084, encodeId=0b491059084f4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059083, encodeId=6955105908372, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:23 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059082, encodeId=dec5105908230, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2d5629732, createdName=ms4000000833791793, createdTime=Sun Oct 10 01:56:20 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-10-10 ms4000000833791793

    学习

    0

拓展阅读

2016 BAP指南:精神病和抗精神病药物治疗相关性体重增加,代谢紊乱和心血管风险的管理

英国精神药理协会(BAP,British Association for Psychopharmacology) · 2016-05-04

2016 应用长效可注射性抗精神病药物治疗精神分裂症:证据评估

国外精神科相关专家小组(统称) · 2016-09-01

2020 AMP专家共识:并存内科和精神科疾病成人患者的QTc监测

国外精神科相关专家小组(统称) · 2020-05-11

2023 DPWG指南:CYP2D6, CYP3A4和CYP1A2与抗精神病药物之间的基因-药物相互作用

荷兰药物基因学工作组(DPWG,Dutch pharmacogenetics working group) · 2023-03-31